Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses targeted therapies in endometrial cancer.

There was a gynecologic study that showed that the combination of the mTOR inhibitor everolimus (Afinitor) and letrozole provided prolonged benefit in a patient with an mTOR mutation.

Regimens of EZH2 inhibitors in patients with 

 mutations, as well as MEK inhibitors, are also in the pipeline and are worth consideration, says Arend.

Rebecca Arend, MD

Articles

Dr. Arend Discusses Targets in Endometrial Cancer